Key statistics
On Friday, Shanghai Junshi Biosciences Co Ltd (688180:SHH) closed at 32.47, 40.68% above the 52 week low of 23.08 set on Sep 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.30 |
---|---|
High | 35.30 |
Low | 32.02 |
Bid | 32.47 |
Offer | 32.51 |
Previous close | 34.41 |
Average volume | 10.93m |
---|---|
Shares outstanding | 985.69m |
Free float | 687.60m |
P/E (TTM) | -- |
Market cap | 29.43bn CNY |
EPS (TTM) | -1.96 CNY |
Data delayed at least 15 minutes, as of Oct 11 2024 08:00 BST.
More ▼
Announcements
- Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
- Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
- Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
- Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
- Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
More ▼